Home Health Encounter + Patient Monitoring + Questionnaire Administration + NIVOLUMAB for carcinoma, transitional cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 Feb 2024: Trial registered, NCT06265285
  2. 30 Apr 2024: Trial started, NCT06265285

The trials

NCT06265285: Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

State
Under way
Phase
Phase 2
People
50 planned
Started
30 Apr 2024
Primary completion
1 May 2027
Arms
Health services research (in-clinic and at-home nivolumab)
Results
None posted
  1. 20 Feb 2024: Trial registered
  2. 30 Apr 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.